The field of stromal immunology has risen to prominence in the last decade, fuelled by accumulating evidence that nonhaematopoietic mesenchymal cells are not simply involved in modulating tissue structure, but actively contribute to immune processes. In addition to regulating tissue integrity during homoeostasis, stromal cells are sensitive sensors of inflammatory stimuli produced downstream of tissue injury or infection, and respond by producing a wide variety of chemokines, cytokines and adhesion factors that contribute to immunity and tissue repair. When not appropriately regulated, these same processes can result in inflammatory pathology and organ dysfunction. In this review, we provide a brief overview of stromal immunology, followed by a comprehensive discussion of how the IL-6 family cytokine oncostatin M (OSM) coordinates stromal cell activity in diverse physiological and pathological contexts. We conclude by providing a perspective on the potential clinical value of the OSM-stromal cell axis and how this pathway might be exploited therapeutically.
| STROMAL CELLS: ACTIVE CONTRIBUTORS TO IMMUNITY AND INFLAMMATION
Long considered as merely structural entities with no active roles in tissue-specific or systemic immune responses, a wealth of evidence has emerged over the past two decades that establishes nonhaematopoietic stromal cells as key mediators of both protective and pathological immune responses, leading to the emergence of the specialized field of "Stromal Immunology". 1 In this review, the term "stromal cells" refers to various nonhaematopoietic, nonepithelial populations of mesenchymal origin, including fibroblasts, endothelial cells, muscle cells, adipocytes and osteoblasts.
The concept of stromal cells as active contributors to immunity and inflammation grew from studies of the nonhaematopoietic cellular compartment of secondary lymphoid organs. From the first identification of a lymph node stromal cell subset (gp38-expressing fibroblastic reticular cells) in 1992, 2 the field has developed significantly, with at least 10 distinct subsets of stromal cells now identified in the lymph node alone. 3 Stromal cells play a critical role in the initiation of both homoeostatic and inflammatory lymphoid tissue development, 4 as well as having an array of direct and indirect effects on haematopoietic immune cells. 5 It is these abilities to both stimulate and respond to "classical" immune cells that underlies the newly appreciated importance of stromal cells in immune responses in many tissues, including those beyond the lymphoid organs.
Rheumatoid arthritis (RA) provides an excellent example of the inflammatory capabilities of stromal cells. Synovial stromal cells play a key role in the chronic inflammation associated with RA by sensing cytokines such as tumour necrosis factor alpha (TNF-α) and, in response, driving chemokine production, immune cell recruitment, inflammatory cytokine production and ultimately tissue destruction. 6, 7 Intriguingly, it appears that many inflammatory signals are "imprinted" within synovial stromal cells, giving rise to the hypothesis that stromal cells drive the chronicity of inflammation, in RA and other chronic inflammatory conditions. 8 Intestinal stromal cells (iSCs) are also known to contribute to both protective and pathological immune responses. Human iSCs express a diverse array of innate immune receptors, such as TLRs (Toll-like receptors) and NLRs (NOD-like receptors), that allow them to directly sense and respond to both isolated microbial products as well as live enteric bacteria. Furthermore, they can both process and present antigen. 9 This places them in a similar functional position to "professional" innate immune cells, although these functions are generally less pronounced compared with highly specialized haematopoietic populations. iSCs are prodigious producers of cytokines and chemokines, and it is highly likely that immunological signals (either inflammatory or homoeostatic) may also be imprinted in iSCs. 10, 11 iSCs are known to interact directly with several subsets of haematopoietic immune cells in the intestine 12 and may play a role in maintaining T cell tolerance at steady state. 13 Furthermore, stromal cell signatures are known to correlate with poor therapeutic response in colorectal cancer, 14 although it is not clear whether this results from stromal cell suppression of protective T cell responses, as seen in other tumour types. 15, 16 Despite significant progress in identifying stromal cell pathways that modulate homoeostasis and inflammation, there remain important gaps in our knowledge, particularly relating to novel pathways that regulate stromal cell function. Given the known key role of a specific cytokine (lymphotoxin; LT) in the activation of lymph node stromal cells, 17 identifying dominant cytokines that regulate stromal cells in other tissues represents an important approach for unravelling stroma-specific mechanisms that can be exploited for therapeutic intervention. In this review, we discuss in detail the biology of oncostatin M (OSM), a pleiotropic cytokine of the IL-6 family that potently modulates stromal cell behaviour in numerous tissues and organs. Because general OSM biology has been reviewed elsewhere, 18, 19 we focus primarily on physiological functions of OSM that have a known or suspected basis in stromal cell activation. We conclude by offering a perspective on the potential clinical implications of the OSM-stromal cell axis, and the challenges that remain in understanding its biology.
| A BRIEF INTRODUCTION TO ONCOSTATIN M (OSM)

| Discovery and ligand-receptor relationships
OSM was first identified in 1989 as a factor produced by U937 lymphoma cells and was named for its ability to inhibit melanoma cell proliferation in vitro. 20, 21 In the nearly 30 years since its discovery, OSM has been shown to influence numerous homoeostatic and pathological processes (Figure 1 ), yet its biology remains obscure in comparison with many other cytokines, including its most well-known family member, interleukin-6 (IL-6). Like other members of the gp130 cytokine family, OSM displays a compact four-helix bundle topology and engages receptor complexes comprised of gp130 and a ligand-specific receptor subunit. In conjunction with gp130, human OSM can signal via either the LIFR or OSMR receptor proteins. 18, 19 These are sometimes referred to respectively as "Type I" and "Type II" complexes, which do not reflect a biological hierarchy, but rather the order in which they were discovered. In both cases, OSM can engage gp130 with low affinity, but signalling requires further recruitment of OSMR or LIFR, which form high-affinity, signalling-competent trimers with OSM and gp130. [22] [23] [24] Importantly, OSMR, LIFR and gp130 all possess intracellular domains that propagate signal transduction cascades (described further below). In contrast, the alpha receptors for IL-6 and IL-11 have no signalling capacity, so signal transduction from these cytokines emanates solely from gp130. 25, 26 In general, mouse OSM is thought to engage only gp130/OSMR complexes with high affinity. 27, 28 However, mouse OSM was recently reported to influence bone turnover in a LIFR-dependent fashion, suggesting that signalling by a low-affinity OSM/gp130/LIFR complex may be sufficient to exert biological effects in some settings. 29, 30 Although the structural details of ligand-receptor interaction have been elucidated for other members of the OSM cytokine family (including LIF and IL-6), no highresolution structures of OSM-receptor interaction have been reported. Nevertheless, site-directed mutagenesis of OSM has helped identify several residues that are critical for receptor interaction. These include Q16, Q20, G120 and N124, which form a cluster on the A and C helices that is necessary for binding to gp130, and two solvent-exposed residues on helix D (F160 and K163) that mediate interaction with LIFR or OSMR. 
| OSM-induced signal transduction
Although gp130 is ubiquitously expressed, cell type specificity for OSM is bestowed by the more restricted expression of LIFR and OSMR. LIFR is expressed at low levels by various epithelial, haematopoietic and mesenchymal cell types in adult tissues and plays key roles in embryogenesis. 32 OSMR, in contrast, is highly expressed by various nonhaematopoietic mesenchymal cells, including fibroblasts, endothelial cells, smooth muscle cells, osteoblasts and adipocytes, as well as hepatocytes, mesothelial cells, glial cells and epithelial cells from several organs. 18, 19, 33 Whether OSMR is expressed at physiologically relevant levels by haematopoietic cells is less clear, but it may be expressed by monocytes following exposure to microbial stimuli or other activating signals, 34, 35 and possibly some macrophage populations. 36 Because expression of LIFR is not generally associated with pathological processes, and studies of OSM typically report critical roles for OSMR (but not LIFR) in mediating OSM biology, this review will focus on biology related to the OSM-OSMR axis unless otherwise noted. In common with other cytokine receptors, the intracellular domains of gp130 and OSMR do not possess intrinsic kinase activity. Signal transduction is instead initiated by receptor-associated Janus kinases (JAKs), which are brought into close proximity upon ligand-receptor interaction and transphosphorylate each other at conserved tyrosine residues. This is followed by phosphorylation of various tyrosine residues in the intracellular receptor domains that serve as recruitment sites for downstream mediators. 37 The ability of OSM to transduce signals via two distinct receptor chains (gp130 and OSMR) gives it a broad signal transduction profile in comparison to IL-6, which relies solely on gp130 for signalling (Figure 2) . 18, 19, 37 While JAK1 is essential for IL-6 signalling, OSM signals are propagated by both JAK1 and JAK2. 38 Downstream of JAK activation, major pathways activated by IL-6 include the MAPK (mitogen-activated protein kinase) cascade, the PI3K (phosphatidylinositol-3-kinase) cascade and STAT3 (signal transducer and activator of transcription-3). 26 60 T cell receptor (TCR) stimulation using anti-CD3 antibodies is sufficient to induce OSM production from T cells through an uncharacterized mechanism. 53 In addition to STAT5, OSM production in murine CD4 + T cells is positively regulated by STAT4 and negatively regulated by STAT6, such that OSM is preferentially complex triggers activation of Jak1 and Jak2, which phosphorylate tyrosine residues in the cytoplasmic domains of gp130 and OSMR (residues shown here correspond to human receptors). The four distal tyrosine residues in gp130 recruit STAT1 and STAT3. The distal two tyrosines in OSMR also recruit STAT3; however, OSMR appears to promote STAT1 recruitment independent of receptor tyrosine phosphorylation, and most likely through direct interaction between STAT1 and Jak1. OSMR can additionally recruit STAT5 via two proximal tyrosine residues. OSM is reported to induce STAT6 activation in mouse cells through an uncharacterized mechanism. STATs 1, 3, 5 and 6 are then tyrosinephosphorylated and translocate to the nucleus, where they control transcription of diverse target genes. For example, STAT1 activates expression of several interferon-response genes including IRF1 and IRF7. In addition to STATs, gp130 and OSMR activate the RAS-MAPK cascade via SHP2 and Shc, respectively. SHP2 primarily drives ERK1/2 activation, while Shc mediates activation of ERK1/2, JNK and p38. ERK1/2 also promotes PI3K activation via the adaptor Gab1. OSM-induced signalling is negatively regulated by SOCS3, expression of which is driven by both STAT3 and ERK1/2
expressed by Th1 cells. 53 This is consistent with a prior observation that newly differentiated human Th1 cells express 20-fold more OSM mRNA than their Th2 counterparts. 70 
| Regulation of OSMR expression
Little is known about the regulation of OSMR. OSM itself can promote OSMR expression, 44, [77] [78] [79] suggesting that other cytokine signals may have a similar effect. Intriguingly, parathyroid hormone has been shown to induce OSMR expression in osteoblasts. 80 OSMR is expressed largely by various nonhaematopoietic cell types and found in virtually every organ (see GTEx RNA-seq data set: https:// www.gtexportal.org/home/gene/OSMR). OSMR can be expressed by some types of epithelial cells, such as those of the mammary gland and skin. However, it is largely absent from intestinal epithelial cells, 11 demonstrating that OSMR expression is not a universal feature of epithelial differentiation. Probably the most widely distributed OSMR + cell types are those of mesenchymal origin, particularly fibroblasts and endothelial cells. Because these cell types are ubiquitous, OSM/OSMR signalling may serve as an axis of immune-stromal cell crosstalk in a wide variety of tissues and physiological settings. The remainder of this review is devoted to exploring our current understanding of OSM-stromal biology, the physiological scenarios in which it may be involved, and its relevance to human disease.
| OSM IN THE REGULATION OF BONE HOMOEOSTASIS AND PATHOLOGY
Several IL-6 family cytokines, including OSM, can regulate physiological bone turnover. However, they differ from each other with respect to their cellular source, target cell type and mechanism of action. 81 The importance of gp130 signalling during skeletal development was recently emphasized by the identification of a hypomorphic missense mutation (N404Y) in IL6ST (the gene encoding gp130) that attenuates signalling by IL-6, IL-11, IL-27 and OSM, but does not strongly affect LIF. 82 In addition to various immunodeficiencies, the single affected patient displayed skeletal abnormalities including craniosynostosis and progressive scoliosis. 82 This section will briefly summarize the role of OSM in regulating bone homoeostasis under healthy and pathological conditions. For more detailed discussion of this subject, the reader is referred to two excellent reviews. 33, 81 Bone is a notable example of tissue in which OSM is derived from both haematopoietic and nonhaematopoietic sources, including macrophages, T cells, osteoblasts and osteocytes. 33 OSM has long been known to promote bone catabolism and osteoclast production in vitro. 83, 84 In osteoblast-bone marrow coculture systems, OSM/OSMR signalling stimulates osteoblasts to express RANKL (receptor activator of nuclear factor κB ligand) in a STAT3-dependent manner, which in turn supports osteoclast differentiation. 30, 85 Indeed, osteoblasts from Osmr −/− mice are unable to support osteoclast formation from wild-type bone marrow in vitro, 30 and OSM treatment stimulates calcium release from mouse bone explants. 84 These findings are consistent with the osteoclast deficiency observed in Osmr −/− mice. 30, 86 Intriguingly, however, mice with gp130 deficiency restricted to the osteoblast lineage do not show alterations in osteoclast abundance in vivo. 87 Therefore, the osteoclast deficiency observed in Osmr −/− mice is likely unrelated to the mechanism by which OSM promotes osteoclastogenesis in vitro. It should be noted that OSMR does not act exclusively as an OSM receptor; along with IL-31RA (also called gp130-like cytokine), it is also a critical receptor subunit for IL-31. 34 Although IL-31 was not found to influence osteoclast differentiation in vitro, 30 IL-31 signalling via OSMR could potentially affect osteoclast production or maintenance in vivo. The ability of OSMR to transduce signals by both OSM and IL-31 is a complexity that should be considered when interpreting any data derived from OSMR knockout mice.
In apparent contrast to its proposed role in promoting osteoclast differentiation, OSM has been shown by multiple investigators to promote bone anabolism. Mice with gp130 deficiency in osteoblasts display decreased trabecular bone mass, suggesting that gp130-family cytokines act directly on the osteoblast lineage to promote bone formation. 87 Given the ability of OSM to influence both osteoblast and osteoclast activity, it is reasonable to predict that dysregulated OSM signalling could be pathogenic. Indeed, macrophage-derived OSM was recently shown to promote the development of neurogenic heterotopic ossifications (NHOs; ectopic bone formation in soft tissues surrounding joints after spinal cord trauma). 61 In both mouse and human muscle-derived stromal cells, OSM promoted osteoblastic differentiation and calcium mineralization, and Osmr −/− mice were resistant to ectopic bone development in a preclinical model of NHO. 61 In contrast, adenoviral delivery of exogenous OSM to mouse joints has been shown to promote inflammation and bone erosion. 90 Whether the bone-erosive phenotype was directly induced by OSM or other downstream inflammatory mediators was not addressed. These studies demonstrate that excess OSM can, either directly or indirectly, promote bone overgrowth or bone destruction in different pathological contexts.
| OSM AND JOINT INFLAMMATION
OSM has long been implicated as a driver of joint inflammation. Over 20 years ago, OSM protein was found at high levels in the synovial fluid of patients with rheumatoid arthritis, but not patients with osteoarthritis (which is not generally thought to have an inflammatory aetiology). [91] [92] [93] [94] OSM has since been shown in a large number of studies to modulate production of numerous inflammatory and matrix remodelling factors by stromal cells of the joint, including synovial fibroblasts and osteoblasts. 18 Inflammatory mediators and cytokine receptors that are induced in these cell types following OSM treatment include IL-6, CCL2, CCL13, CXCL1, IL1R1, ICAM1, OSMR and gp130. 91, [95] [96] [97] [98] [99] [100] [101] A recent study of mouse chondrocytes provided an unbiased whole-transcriptome analysis of short-term OSM stimulation and reported over 1800 OSM-regulated genes, many of which were associated with processes related to host defence and wound healing. 102 These observations imply that OSM can support leucocyte recruitment, retention and activation in the joint, as well as bolster stromal cell sensitivity to cytokines by promoting expression of cytokine receptor genes. Indeed, intra-articular adenoviral delivery of OSM, but not IL-6, to mouse knees was sufficient to induce a robust inflammatory response that included large numbers of infiltrating leucocytes, synovial hyperplasia and degradation of cartilage and bone tissue. 90, 96, 103 In a separate study, blockade of OSM using a polyclonal antibody substantially attenuated the severity of collagen-induced arthritis in mice and completely prevented the onset of arthritis in pristane-challenged animals, 104 identifying OSM as a potential nonredundant driver of synovial immunopathology. In addition to promoting leucocyte accumulation in the joint, OSM can directly modulate cartilage turnover and extracellular matrix (ECM) remodelling. OSM induces high levels of TIMP-1 (tissue inhibitor of metalloproteinases-1) expression by synovial fibroblasts, suggesting that OSM may limit ECM degradation. 93, 96, 97, 103, 105 This is inconsistent with the effects of OSM described in preclinical arthritis models, but can be explained by functional synergism between OSM and other inflammatory cytokines. Chondrocytes and synovial fibroblasts strongly upregulate MMPs (matrix metalloproteinases) when costimulated with OSM and either TNFα, IL-1β or IL-17A. 91, 97, 103, 106 This synergistic effect results in high MMP/TIMP ratios and net collagen and proteoglycan degradation in cartilage explant systems. Other target genes are also induced synergistically by these cytokines, including IL-6 and RANKL. 95, 97, 101 Consistent with these in vitro findings, intra-articular overexpression of OSM and TNFα or OSM and IL-1β causes greater joint destruction than any one cytokine alone. 90, 103, 107 Thus, OSM may be an important mediator of arthritic pathology, but this conclusion is limited by a lack of studies that test whether joint inflammation requires OSM in vivo (only one has been published to date using polyclonal anti-OSM antibodies 104 ). Notably, phenotypes of Osm −/− or Osmr −/− mice in arthritis models have not been reported. 62, 113 Notably, OSM expression had no effect on myeloid colony formation in vitro, suggesting a microenvironment-conditioning effect in vivo. 113 Expression of Flt3 with an internal tandem duplication (ITD; a gain-of-function mutation found frequently in human acute myeloid leukaemia) in mouse bone marrow causes a myeloproliferative neoplasia in which OSM is highly expressed. 62 In contrast, expression of a tyrosine kinase domain-mutated (TKD) Flt3 causes lymphoproliferative disease without marked OSM expression. In this model, ectopic OSM expression in Flt3-TKD bone marrow switched the disease to a myeloproliferative phenotype similar to that observed with Flt3-ITD. 62 Thus, aberrant OSM expression appears to preferentially promote myeloproliferative neoplasia in mice, but not lymphoproliferative disease. OSM is also expressed at high levels by neoplastic mast cells expressing the activating D816V KIT mutation, by myeloid cells expressing the activating V617F JAK2 mutation and by eosinophils expressing the FIPL1/ PDGFRA oncogene. [63] [64] [65] In each case, OSM production was shown to stimulate human stromal cells in vitro. For example, microvascular endothelial cells, osteoblasts and bone marrow fibroblasts proliferated in response to leukaemia-derived OSM, 65 while lung fibroblasts expressed CXCL12 and VEGF (vascular endothelial growth factor). 63, 64 Thus, OSM may promote myeloid neoplasia by acting on stromal cells within the leukaemic niche, but this has not been formally demonstrated using whole-body or conditional OSMR-deficient mice.
| REGULATION OF HAEMATOPOIESIS AND THE BONE MARROW NICHE BY OSM
| ACTIVATION OF ENDOTHELIAL CELLS BY OSM
OSM was initially discovered as a growth regulator of cancer cells, and it was first connected to vascular biology in this respect. Several papers in the early 1990s identified OSM as a potent mitogen for AIDS-related Kaposi's sarcoma spindle cells, 55, 114, 115 which are now thought to be derived from dedifferentiated lymphatic endothelium. 116 In cultures of human microvascular endothelial cells (HMEC), OSM was a stronger stimulant of cell proliferation and tube formation than the classical angiogenic factors VEGF and FGF2 (fibroblast growth factor-2), whereas LIF and IL-6 had relatively little effect. 117 OSM can also promote chemotaxis of HMEC in vitro. 117 Direct stimulation of endothelial cells by OSM may also impact the evolution of inflammatory responses. OSM induces endothelial expression of several adhesion factors and cytokines, including P-selectin, E-selectin, ICAM1, VCAM1, IL-6, CCL2 and the neutrophil chemoattractants CXCL1, CXCL2 and CXCL5. [130] [131] [132] [133] Induction of neutrophil rolling and adhesion on human endothelial cells stimulated with OSM was dependent on P-selectin induction. 131, 132 Whether OSM is required for this process in vivo is unknown.
| OSM AND THE CARDIOVASCULAR SYSTEM
Cardiac fibroblasts and myocytes were shown a decade ago to express CXCL12 and the neutrophil chemokines CXCL1, CXCL2 and CXCL5 in response to OSM treatment, raising the possibility that OSM could modulate inflammation following cardiac tissue injury. 110, 134 OSM was later found at high levels in plasma and heart tissue from patients with heart failure. 135, 136 Importantly, OSM was shown to promote cardiomyocyte dedifferentiation and tissue remodelling after acute injury (eg cardiac infarct), which contributed to tissue repair and retention of organ function. 136, 137 In contrast, persistent OSM production and prolonged cardiomyocyte dedifferentiation contributed to heart failure associated with dilative cardiomyopathy. Indeed, after acute myocardial infarct, Osmr −/− mice showed substantially reduced survival, while treatment with recombinant OSM had a protective effect. Conversely, loss of OSMR function protected mice from inflammatory dilative cardiomyopathy, 136, 138 suggesting that unchecked OSM signalling contributes to progressive organ dysfunction by blocking differentiation of mature cardiomyocytes. OSM is also reported to limit damage from acute myocardial infarct and diabetic ischaemia-reperfusion injury by promoting autophagy and inhibiting apoptosis in cardiomyocytes. 139 143 Thus, based on these observations and those from studies of cardiac injury, chronic OSM signalling likely has a net pathogenic effect on the cardiovascular system, while appropriately regulated OSM signalling may be tissue-protective.
| OSM-STROMAL CELL BIOLOGY IN BARRIER TISSUES
OSM has been linked to inflammatory processes in several barrier/mucosal organs, including the skin, lung and intestine. Most studies of OSM in the skin have focused on keratinocytes, which express high amounts of OSMR and produce a wide array of cytokines, chemokines and antimicrobial proteins in response to OSM treatment. 51 However, dermal fibroblasts also respond to OSM by proliferating and increasing their production of extracellular matrix components, including collagen I, collagen III and various glycosaminoglycans. [144] [145] [146] Furthermore, OSM induces expression of several classical interferon-stimulated genes in dermal fibroblasts in a STAT1-dependent manner, including the viral double-stranded RNA sensors RIG-I and MDA5, suggesting that it may be involved in antiviral immunity. 40 Although OSM stimulation is sufficient to induce skin inflammation in vivo, it is dispensable in the imiquimod model of psoriasis-like inflammation. 11, 147 Like the joint, administration of exogenous OSM to the lower respiratory tract, either in the form of recombinant protein or OSM-encoding adenovirus, is sufficient to induce lung inflammation and tissue remodelling. 79, [148] [149] [150] Exogenous OSM induces infiltration of the lung parenchyma by macrophages, lymphocytes, neutrophils and eosinophils, and triggers rapid changes in expression of diverse cytokines and chemokines. 79 Intriguingly, the effect of OSM on murine lung inflammation may depend on genetic background. In a study comparing the effects of OSM on BALB/c and C57BL/6 mice, lymphocyte recruitment and neutrophil recruitment to the lung were observed in both strains after infection with OSM-expressing adenovirus, but lung eosinophilia, expression of eotaxin (CCL11; a potent eosinophil chemoattractant) and induction of a Th2 response were observed only in C57BL/6 mice. 148 Notably, OSM-neutralizing antibodies attenuated the severity of asthmatic airway inflammation in mice treated intranasally with follistatin-like-1 (Fstl1), an inflammatory mediator found at high levels in the lungs of patients with severe asthma. 151 Although the specific cell types through which OSM mediates lung inflammation have not been identified, several studies suggest a contribution by stromal cells. Consistent with the eosinophilic effect of OSM in vivo, OSM-induced ERK1/2 and p38 MAPK signalling activate expression of eotaxin by mouse lung fibroblasts, whereas other members of the gp130 cytokine family have little or no effect.
149 Surprisingly, OSM can induce STAT6 signalling in lung fibroblasts, which is also required for induction of eotaxin by OSM alone or in combination with IL-4. 41 OSM and either IL-4 or IL-13 can also synergistically induce eotaxin expression by airway smooth muscle cells. 152 Beyond eotaxin, OSM stimulates lung fibroblasts and smooth muscle cells to express various other factors such as IL-6, CCL2, VEGF and MMPs, which can be synergistically induced by the addition of IL-1β, TNF or IL-17A. 73, 124, [152] [153] [154] For reasons unknown, OSM-induced expression of VCAM-1 on lung fibroblasts and endothelial cells was recently shown to depend on TRAF5 (TNF receptor-associated factor 5), and TRAF5-deficient mice were resistant to lung inflammation induced by intranasal OSM treatment. 155 Unlike skin keratinocytes, normal intestinal epithelial cells do not express high levels of OSMR and are weakly responsive to OSM stimulation, although some colorectal cancer cell lines are OSM-responsive. 11, 156 In contrast, in both mice and humans, OSMR is found at high levels on intestinal fibroblasts and, to a lesser extent, endothelial cells.
11
Both OSM and OSMR are substantially overexpressed in the inflamed intestinal tissue of patients with inflammatory bowel disease (IBD), and their expression levels correlate with clinical nonresponsiveness to standard-of-care anti-TNF antibodies (eg infliximab and golimumab). 11 In a mouse model of anti-TNF resistant IBD, Osm −/− mice or animals treated with an OSM-neutralizing agent showed reduced colitis severity and reduced expression of a gene signature associated with anti-TNF resistance in human IBD patients. 11 Intestinal fibroblasts responded to OSM in an OSMR-dependent manner by expressing many of the same response genes as fibroblasts from other organs, including IL-6, ICAM1 and various chemokines. 11 Adenoviral overexpression of OSM may influence disease course in additional models of IBD, including the DSS (dextran sodium sulphate) model of acute barrier disruption, in which excess OSM was mildly protective, and the oxazolone model of hapten-induced colitis, which may be exacerbated by excess OSM. 157 Although the gene expression pattern of intestinal OSMR strongly suggests that mesenchymal cells mediate OSM biology in the intestine, experiments involving lineage-specific deletion of OSMR are required to confirm this hypothesis.
| REGULATION OF ADIPOCYTES AND METABOLISM BY OSM
OSM appears to control the fate of mesenchymal progenitors by promoting osteoblastic differentiation at the expense of adipogenesis. 30, 71, 112, 158, 159 Furthermore, OSM induces dedifferentiation of mature adipocytes in vitro. 160 In genetically obese leptin-deficient mice (ob/ob mice) or animals fed a high-fat diet, expression of OSM and OSMR was increased in adipose tissue. [161] [162] [163] Similarly, OSM expression is elevated in adipose tissue from obese humans. 162 Consistent with a role for OSM in the negative regulation of lipogenesis, aged Osmr −/− mice develop obesity, adipose tissue inflammation, liver steatosis and insulin resistance. 35, 161 Notably, this phenotype was attributed to a direct effect of OSM on adipose tissue macrophages, which were shown to express OSMR and adopt an M2 polarization state in response to OSM. 35 A potential role for OSM signalling in macrophages was supported by an independent study of mice with adipocyte-specific deletion of OSMR. Unlike whole-body Osmr −/− mice, these animals did not develop increased adiposity, although they still displayed increased adipose tissue inflammation and insulin resistance following feeding on a high-fat diet. 164 However, because OSMR was deleted in mature adipocytes in this study, a potential role for OSM signalling in adipocyte precursors could not be addressed.
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IN FIBROSIS
Progressive loss of organ function due to fibrosis is a serious and common complication of many chronic inflammatory disorders. The ability of OSM to activate stromal cells under inflammatory conditions raises the question of whether OSM can influence fibrotic pathogenesis, but few studies have directly addressed this possibility. Notably, OSM is capable of high-affinity interaction with extracellular matrix components that are prevalent in fibrotic tissues, such as collagens and fibronectin, and maintains biological activity while bound to these proteins. 165, 166 This property was not observed for other gp130-family cytokines, 165 raising the intriguing possibility that bioactive OSM protein can accumulate in fibrotic tissues through interaction with the ECM. Exogenous OSM production in the lungs of otherwise healthy mice is sufficient to induce pulmonary fibrosis, 79, 148, 150 and OSM blockade attenuates peribronchial fibrosis in an Fstl1-driven mouse model of severe asthma, suggesting that OSM may indeed be a relevant mediator of fibrosis in the lung. 151 In humans, OSM is expressed at abnormally high levels by peripheral blood mononuclear cells from patients with systemic sclerosis, 167 an inflammatory disease for which pulmonary fibrosis is a common and life-threatening complication. Furthermore, OSM was identified as part of a profibrotic gene signature expressed by lung-resident CD8 + T cells in patients with systemic sclerosis. 54 Consistent with findings from lung fibrosis models, overexpression of OSM in bone marrow was shown to cause extensive marrow fibrosis in the context of myeloproliferative neoplasia. 113 In contrast to these studies, virally mediated OSM expression was shown to protect rats from hepatic fibrosis in the dimethylnitrosamine model of liver damage, 168 an effect that likely depended on OSM-induced hepatocyte regeneration. However, repeated delivery of an OSM-expression vector to the livers of healthy mice by hydrodynamic tail vein injection resulted in pronounced liver fibrosis that featured high levels of Timp1 and Col1a1 expression. 36 Furthermore, Osm −/− mice were protected from liver fibrosis in the thioacetamide model of chronic hepatitis. 36 Notably, OSM-mediated liver fibrosis was shown to be driven by both hepatic stellate cells, which expressed TIMP-1 in response to OSM, and liver macrophages, which responded to OSM by expressing the fibrogenic mediators TGF-β1 and PDGF-B. 36 Thus, the available evidence suggests that OSM can indeed promote fibrosis, but further studies of OSM loss of function in relevant fibrosis models are required to confirm this hypothesis.
| REGULATION OF OTHER CYTOKINE SIGNALS BY OSM
While OSM alone can elicit diverse responses in mesenchymal cells, a physiologically important property of OSM may be its ability to modify responses to other cytokines ( Figure 3 ). As described in the above sections, OSM synergizes with TNF, IL-1β and IL-17A to drive robust expression of diverse target genes, including MMPs, VEGF, IL-6 and the chemokines CXCL9, CXCL10 and CXCL11. 11, 73, 95, 103, 106, 123, 124, 133, 152, 169 OSM similarly synergizes with IL-4 to induce high levels of CCL11 (eotaxin) expression. 41, 152 Intriguingly, IL-1-or TNF-driven IL-8 expression may be enhanced or repressed by OSM in a context-dependent manner; OSM appears to suppress IL-8 production by fibroblasts and endothelial cells, 95, 133 whereas it synergizes with IL-1 to induce IL-8 expression in chondrocytes. 169 OSM also enhances IL-8 expression in synergy with IL-17A. 152 Based on these findings, the 
| CLINICAL EXPLOITATION OF THE OSM-STROMAL CELL AXIS
Various cytokines, including IL-6, IL-1 and TNF-α, are well established as effective therapeutic targets for inflammatory diseases. However, because of their central role in host defence, drugs targeting these cytokines also confer an increased risk of infection, and therefore must be used cautiously. Whereas IL-6, IL-1 and TNF-α have broad stimulatory capacity in both haematopoietic and nonhaematopoietic cell types, OSMR expression is more restricted to stromal and other nonhaematopoietic populations. Furthermore, a critical role for OSM in antipathogen immunity has not been reported to date. As such, targeting this axis may provide a novel means of inhibiting inflammatory pathology while preserving protective immunity. Like other cytokines, various approaches could be used to target the OSM/OSMR axis therapeutically (summarized in Figure 4 ). OSM can be targeted directly by either monoclonal antibodies or soluble receptor fusion proteins. Indeed, we recently employed a fusion protein comprised of the ligand-binding domains of mouse OSMR and gp130 to neutralize OSM and attenuate pathology in a mouse model of anti-TNF resistant colitis. 11 OSMR could similarly be targeted using neutralizing antibodies. However, unlike OSM, which is expressed highly at sites of active inflammation but not found in high amounts systemically, OSMR is constitutively expressed in various organs and tissues. Anti-OSMR antibodies could thus have poorer pharmacokinetic properties and may damage off-target tissues through antibody-mediated toxicity. Furthermore, OSMR blockade would also attenuate the effects of IL-31, which may not be clinically desirable. Bispecific antibodies that target either OSM or OSMR as well as an additional cytokine or tissue-specific target may also be therapeutically beneficial. Such antibodies could be used to target anti-OSM activity to specific tissues, or to target the cytokine synergies in which OSM participates (Figure 3) . Finally, targeting specific signalling molecules downstream of OSMR is yet another option of manipulating the OSM-OSMR axis. Janus kinase (JAK) inhibitors have been clinically evaluated in various inflammatory diseases, including rheumatoid arthritis, psoriasis and ulcerative colitis, with varying degrees of success. However, because of shared JAK usage between cytokine families, JAK inhibitors are more broadly immunosuppressive than agents that target individual cytokines, a feature that increases risk of infectious adverse events. 170 Similar challenges exist for other signalling mediators downstream of OSMR, such as the MAPK pathway. Beyond acting as a therapeutic target, the OSM-stromal cell axis could serve as a novel source of clinical biomarkers. Effective delivery of personalized therapy to patients with inflammatory diseases is hampered by a lack of biomarkers that can be used to predict disease course and treatment response. In IBD, for example, anti-TNF monoclonal antibodies are well established as effective therapies. Nevertheless, up to 40% of patients are nonresponsive to anti-TNF agents, 171, 172 and no clinically accepted methods of treatment response prediction currently exist. 173 Notably, unlike standard clinical parameters like serum C-reactive protein, high OSM expression in the intestinal mucosa of patients with IBD was recently shown to correlate closely with resistance to anti-TNF therapy. 11 Expression of several cytokine and chemokine genes induced by OSM in colonic stromal cells was similarly associated with poor response to anti-TNF antibodies. Whether OSM also correlates with response to other forms of therapy or with therapeutic response in other diseases remains unknown. Further prospective clinical studies are required to evaluate the utility of OSM as a predictive biomarker in IBD. Nevertheless, these findings emphasize that accurate prediction of therapeutic response outcomes in inflammatory diseases is possible, and that immunological modulators of stromal cell activity may surprisingly be the key.
| CLINICAL DEVELOPMENT OF OSM-TARGETED THERAPIES
To date, limited attempts to modulate OSM signalling therapeutically have been attempted in humans, and there are currently no FDA-or EMA-approved products targeting the OSM-OSMR axis for any indication. Two humanized monoclonal antibodies (mAbs) designed to neutralize OSM -both generated by GlaxoSmithKline-have entered early phases of clinical testing. GSK315234A was investigated in an unsuccessful phase II trial for rheumatoid arthritis, 174 with a lack of efficacy leading to termination of development (ClinicalTrials.gov Identifier: NCT00674635). More recently GSK2330811, a redesigned OSM-neutralizing mAb, commenced a phase II trial in diffuse cutaneous systemic sclerosis (ClinicalTrials.gov Identifier: NCT03041 025). These two antibodies represent the sum of anti-OSM therapeutic agents that have progressed into clinical investigation. However, evidence suggests that further OSM-targeted assets are or were in preclinical development, including a fully human OSM-targeting mAb (CNTO8212; Janssen) 175 
| CONCLUSIONS AND FUTURE
PERSPECTIVES
OSM has been implicated as a regulator of numerous physiological processes in healthy individuals, including haematopoiesis, bone turnover, and wound repair. This likely stems from its ability to modulate cellular differentiation and reparative immune responses, particularly when acting through stromal cells. However, inappropriate activation of OSM-stromal cell signalling appears to be pathogenic, resulting in aberrant tissue organization and exacerbation of inflammatory processes. Although efforts to target OSM-stromal cell biology in the clinic have thus far been modest, OSM is nevertheless an attractive target for inflammatory and fibrotic diseases, and we anticipate that clinical development of OSM-targeted assets will accelerate. Although OSM biology has been described extensively in the past 29 years, our understanding of the field is far from complete. Definitive assignment of OSM to specific physiological or pathological processes is difficult due to the limited use of genetically based in vivo models that employ animals deficient for either OSM or OSMR. The dual role of OSMR as a receptor for both OSM and IL-31 further complicates the picture; several studies describe phenotypes of OSMR-deficient mice, but few clarify whether the observed biology depends on OSM or IL-31 activity. Increased use of OSM-deficient animals or specific OSM-neutralizing agents will greatly enhance our understanding of OSM biology. Furthermore, the diversity of OSM-responsive cell types has made it challenging to mechanistically dissect OSM activity in vivo. Indeed, our concepts of which populations mediate OSM effects are largely speculative at present and should be refined through the use of animal models with tissue-specific OSMR (or LIFR) deficiency. Clarifying these questions will be critical not only to advance our understanding of OSM biology, but also to design well-informed clinical studies of OSM as a novel therapeutic target or predictive biomarker. 
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